DHODH
Dihydroorotate dehydrogenase (DHODH; EC 1.3.3.1) is a flavin-dependent mitochondrial enzyme that catalyzes the oxidation of dihydroorotate to orotate, the fourth reaction of pyrimidine de-novo synthesis[1]. Pyrimidine bases are essential for cellular metabolism and cell growth, and are considered as important precursors used in DNA (thymine and cytosine), RNA (uracil and cytosine), glycoproteins and phospholipids biosynthesis. Inhibitors of DHODH have proven efficacy for the treatment of malaria, autoimmune diseases, cancer, rheumatoid arthritis and psoriasis. Many of the clinically relevant anti-tumor and immunosuppressive drugs target human dihydroorotate dehydrogenase (hDHODH)[2].
[1] H. Munier-Lehmann et al. On dihydroorotate dehydrogenases and their inhibitors and uses. J. Med. Chem. 2013, 56, 3148-3167.
[2] V.K. Vyas et al. Recent developments in the medicinal chemistry and therapeutic potential of dihydroorotate dehydrogenase (DHODH) inhibitors. Mini Rev. Med. Chem. 2011, 11, 1039-1055.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 3164 | Leflunomide | Selective inhibitor of de novo pyrimidine synthesis; DMARD | €60.00 | |
| 2377 | Vidofludimus | Oral immunomodulatory drug that inhibits dihydroorotate dehydrogenase (DHODH) | €125.00 | |